PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
4Kscore May Help Predict Adverse Pathology at Radical Prostatectomy
In a study, a higher 4Kscore was significantly associated with a 16% greater risk of biochemical recurrence of prostate cancer following radical prostatectomy. -
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found. -
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease. -
Prostate Cancer Immunotherapy Alone Is Not Enough
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review. -
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators. -
Fewer Systematic Biopsy Cores May Not Lower PCa Detection Rate
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Latest Prostate Cancer News
Targeted Radiotherapy Improves Outcomes in Previously Treated mCRPC
An investigational targeted radiotherapy added to standard of care improved survival in men with previously treated mCRPC.
Genomic Landscape of Prostate Cancer Differs by Ancestry, but Frequency of Actionable Alterations Is Similar
The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.
TAK-700 Improves PFS, Not OS, Compared With Bicalutamide in Metastatic Hormone-Sensitive Prostate Cancer
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.
Prostate Cancer Therapeutic Decision-Making Is Better Informed With an Expanded Genetic Panel
Results of a multicenter study reveal differences in genetic testing in patients with prostate cancer who meet NCCN guidelines compared with those who do not.
Prostate Cancer Care Declined During the COVID-19 Pandemic
How the decline in health care visits will affect prostate cancer outcomes still needs to be determined.
Kidney Transplantation Not Linked to Higher Prostate Cancer Mortality
Study findings suggest that men with end-stage kidney disease and localized or regional prostate cancer do not need to wait additional time for a kidney transplant because of the cancer.
Study: Advanced Therapies Underused for First-Line mCSPC Treatment
Most men with metastatic castration-sensitive prostate cancer (mCSPC) in 2018 did not receive advanced therapies in addition to androgen deprivation therapy (ADT) as first-line treatment for their disease as recommended by clinical practice guidelines, according to real-world data presented at the American Society of Clinical Oncology 2021 virtual annual meeting. This lack of therapeutic intensification…
Care No Better for Minority Cancer Patients With Medicaid Expansion
No change in receipt of definitive care reported for minorities in expansion states versus nonexpansion states
FDA Approves Tracer That Improves Detection of Advanced Prostate Cancer
Tracer is injected into the bloodstream and lights up metastatic prostate cancer cells during PET scan
Increased Intensity of PSA Screening May Reduce Racial Disparities in Prostate Cancer
Screening intensity was predictive of disease stage and mortality risk.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
Loading... 
Loading...